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BRAIN NATRIURETIC PEPTIDE AS AN INDICATOR OF LEFT VENTRICLE  
DYSFUNCTION AND A PREDICTOR OF CARDIOVASCULAR EVENTS  
IN ACUTE CORONARY SYNDROMES 
 
Nugroho, M. Yogiarto 
 
 
ABSTRACT 
 
Background: Acute coronary syndromes can cause systolic and diastolic left ventricle (LV) dysfunction. Determination 
of LV dysfunction in ACS provides benefit to stratification and optimizing therapy. Brain Natriuretic Peptide (BNP) is 
secreted primarily from and synthesized in left ventricle in response to increased myocardial stretch. BNP increase in 
heart failure. BNP increase in the 24 hours in acute myocardial infarction. We hypothesized that BNP level could be as 
an indicator of systolic and diastolic dysfunction and a predictor of cardiovascular events in acute coronary syndromes. 
Objective: To investigate plasma level of BNP in systolic and diastolic dysfunction in acute coronary syndromes 
hospitalized to ICCU. To investigate plasma level of BNP as a predictor of cardiovascular events in acute coronary 
syndromes. Method and Result: We measured BNP in plasma specimen obtained 3 days after the onset of ischemic 
symptoms in 25 patients of acute coronary syndromes and prospectively followed the patients for 30 days. Patients 
diagnosed with evidence of systolic LV dysfunction had a mean BNP concentration of 301.11 ± 189.62 pg/ml, higher 
than those patients with normal LV function (42.67 ± 22.44 pg/ml, p = 0.003). Patients diagnosed with evidence of 
diastolic LV dysfunction had a mean BNP concentration of 273.70 ± 146.27 pg/ml, higher than those patients with 
normal LV function (42.67 ± 22.44 pg/ml, p = 0.006). Patients with cardiovascular events had a mean BNP 
concentration of 392.30 ± 157.14 pg/ml, higher than patients without cardiovascular events (118.67 ± 78.53 pg/ml, p < 
0.0001). In patients with cardiovascular events, minimum plasma BNP level (248 pg/ml) was higher than maximum 
plasma BNP level in patients without cardiovascular events (234 pg/mL).   Conclusion: Plasma BNP level can reliably 
detect the presence of diastolic or systolic LV dysfunction on echocardiography in acute coronary syndromes. 
Moreover, plasma BNP level can also predict patients with cardiovascular events in 30-days after acute coronary 
syndromes.  
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INTRODUCTION 
 
B-type natriuretic peptide (BNP) is 32 amino acids 
secreted into blood circulation mainly by left ventricular 
myocyte under overload condition or wall stress. BNP is 
a specific indicator of ventricular disturbance and more 
sensitive than other natriuretic peptides. It has 
natriuresis effect, vasodilatation, renin-angiotensin-
aldosteron system inhibition and sympathetic activity 
inhibition (Peacock WF, 2002). 
 
Plasma BNP will increase in patients suffering from 
heart failure and the increase is in accordance with the 
left ventricular dysfunction gradation and the severity of 
heart failure symptoms. In a case of acute myocardial 
infarction, BNP will rise rapidly in the first 24 hours 
(Nagaya N et al, 1998). The researches on plasma BNP 
as prognostic factor in acute myocardial infarction have 
been carried out initially. However, there are merely a 
small number of researches on BNP in patients suffering  
______________ 
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from acute coronary syndromes. The clinical spectrum 
of those patients is heterogeneous. Early finding of 
ventricular dysfunction will be very useful to determine 
patient risk stratification and to give additional 
treatment in order to achieve the optimum treatment 
result (Peacock WF, 2002). 
 
Heart catheterization is a gold standard to evaluate left 
ventricular dysfunction. Nevertheless, it is impractical 
to be used widely or to observe clinical progress of the 
patients. By using Doppler echocardiography as a 
noninvasive technique, the left ventricular dysfunction 
can be evaluated, even though not all patients can easily 
be examined. Plasma BNP is expected as the sign of 
ventricular disturbance in cases of acute coronary 
syndromes. Furthermore, BNP role to predict the 
existence of cardiovascular events is helpful as well to 
find out the prognosis of patients suffering from acute 
coronary syndromes (Lemos JA et al, 2001).  We 
studied BNP role to detect left ventricular dysfunction 
as early as possible and to predict the existence of 
cardiovascular events in cases of acute coronary 
syndromes. 
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MATERIAL AND METHODS 
 
We prospectively studied 25 consecutive patients of 
acute coronary syndromes admitted to the coronary care 
unit Dr Soetomo General Hospital. These patients had 
no prior history of myocardial infarction and heart 
failure. In the third days, we examined 
echocardiography and plasma BNP level. All patients 
were planned for one month of follow up. The local 
scientific ethical committee has approved the study and 
each participant gave informed written consent.  
 
Two-dimensional and pulse Doppler echocardiographic 
examinations were performed using standard cardiac 
ultrasound unit with a 2.5 MHZ transducer. LV systolic 
and diastolic volumes and ejection fraction were 
measured from the apical two and four chamber views 
by modified Simpson’s rule algorithm. The mean of 
three measurements was used and volumes were 
indexes for body surface area. Pulse Doppler recordings 
of the mitral flow velocities were obtained from the 
apical four-chamber view by placing the sample volume 
between the tips of the mitral leaflets. 
 
At the time of enrollment, blood specimens were 
collected in citrate treated tubes and centrifuge for at 
least 12 minutes. The plasma component was frozen. 
After the trial was completed, all available plasma 
specimen analyzed. BNP was measured with the triage 
B-type Natriuretic Peptide test that is a fluorescence 
immunoassay for the quantitative determination of BNP 
in plasma specimens.  
 
Results are presented as mean (+SD). Differences 
between increasing plasma BNP level and LV 
dysfunction groups were examined by ANOVA test. 
The cardiovascular events (death cause of the cardiac 
disease, reinfarction, acute myocardial infarction, heart 
failure) were evaluated at 30 days. Independent t test 
was used to investigate the difference of plasma BNP 
level in patients with cardiovascular events. Values of p 
< 0.05 were considered significant. 
 
RESULTS 
 
This study was carried out on 25 patients suffering from 
acute coronary syndromes consisting of 20 patients 
suffering from acute myocardial infarction, 1 patient 
suffering from non-ST elevation myocardial infarction 
and 4 patients suffering from unstable angina. The left 
ventricular systolic dysfunctions were happened in 9 
patients, the left ventricular diastolic dysfunctions were 
happened in 10 patients and 6 patients had a normal left 
ventricular function. 
 
Table 1. Characteristic of patients suffering from acute coronary syndromes and profile of left ventricular function 
 
 
 
Characteristic 
Left ventricular 
systolic 
dysfunction 
n = 9 
Left ventricular 
diastolic 
dysfunction 
n = 10 
Normal 
left ventricular 
function 
n = 6 
 
Total 
n = 25 
Sex 
Male 
Female 
 
7(77.8%) 
2(22.2%) 
 
7(70.0%) 
3(30.0%) 
 
5(83.3%) 
1(16.7%) 
 
19(76.0%) 
6(24.0%) 
Mean age (year) 56.7 58.7 52.5  
Hypertension 2(22.2%) 5(50.0%) 3(50.0%) 10(40.0%) 
Diabetes mellitus 0(0%) 1(10%) 5(24.0%) 6(24.0%) 
Smoking 6(66.7%) 6(60.0%) 4(66.7%) 16(64.0%) 
Dyslipidemia 7(77.8%) 7(70.0%) 4(66.7%) 18(72%) 
Under the treatment of 
Captopril 
 
6(66.7%) 
 
6(60.0%) 
 
4(66.7%) 
 
16(64.0%) 
Under the treatment of 
thrombolytic therapy 
 
6(66.7%) 
 
2(25.0%) 
 
4(100%) 
 
12(60.0%) 
  
The number of male patients suffering from left 
ventricular systolic dysfunction was 7 persons (77.8%) 
and that of female patients was 2 persons (22.2%). The 
number of male patients suffering from left ventricular 
diastolic dysfunction was 7 persons (70.0%) and that of 
female patients was 3 persons (30.0%). While, another 5 
male patients (83.3%) and 1 female patient (16.7%) who 
suffered from acute coronary syndromes had normal left 
ventricular functions. Mean age were 56.7, 58.7, 52.5 
years old for patients who suffered from left ventricular 
systolic dysfunction, left ventricular diastolic 
dysfunction and normal ventricular function, 
respectively.
 
 
131 
Brain Natriuretic Peptide 
 
Folia Medica Indonesiana                                                                                    Vol. 41 No. 2 April – June 2005  
The risk factors of patients suffering from acute 
coronary syndromes with left ventricular systolic 
dysfunction were dyslipidemia (77.8%, found in 7 
persons), smoking (66.7%, found in 6 persons), and 
hypertension (22.2%, found in 2 persons). The risk 
factors of patients suffering from left ventricular 
diastolic dysfunction were dyslipidemia (70.0%, found 
in 7 persons), smoking (60.0%, found in 6 persons), 
hypertension (50%, found in 5 persons), diabetes 
mellitus (10.0%, found in 1 person). The risk factors of 
patients suffering from acute coronary syndromes with 
normal left ventricular function were diabetes mellitus 
(83.3%, found in 5 persons), dyslipidemia (66.7%, 
found in 4 persons) smoking (64%, found in 4 persons), 
and hypertension (50.0%, found in 3 persons).  
 
The number of patients suffering from acute myocardial 
infarction was 20 persons and 12 persons (60.0%) 
among them were under the treatment of thrombolytic 
therapy. There were 6 patients (66.7%) suffering from 
acute myocardial infarction with left ventricular systolic 
dysfunction who were under the treatment of 
thrombolytic therapy, 2 patients (25%) suffering from 
acute myocardial infarction with left ventricular 
diastolic dysfunction, and 4 patients (100%) with 
normal left ventricular function who were under the 
treatment of thrombolytic therapy. Meanwhile, the 
treatment of Captopril was given to 16 persons (64%), 6 
persons (66.7%) of them suffered from left ventricular 
systolic dysfunction, another 6 persons (60.0%) of them 
suffered from left ventricular diastolic dysfunction and 
the last 4 persons (100%) had a normal left ventricular 
function.  
   
 
 
Table 2. The Distribution of BNP level according to left ventricular function. 
 
Left ventricular 
function 
Number 
n 
Mean 
pg/ml 
Standard 
deviation 
Minimum 
pg/ml 
Maximum 
pg/ml 
ANOVA 
test 
P 
Systolic 
dysfunction 
9 301.11 189.62 88.00 712.00 
Diastolic 
dysfunction 
10 273.70 146.27 97.00 614.00 
Normal 6 42.67 22.44 14.00 64.00 
 
 
0.007 
 
 
The mean of BNP plasma level of patients suffering 
from acute coronary syndromes with left ventricular 
systolic dysfunction was 301.11 pg/ml. The mean of 
BNP plasma level of patients suffering from acute 
coronary syndromes with left ventricular diastolic 
dysfunction was 273.70 pg/ml. Whereas, the mean of 
BNP plasma level of patients suffering from acute 
coronary syndromes with normal left ventricular 
function was 42.67 pg/ml.  P = 0.007 was obtained by 
conducting the ANOVA test on the BNP plasma level 
among the three groups (Table 2). 
 
 
Table 3. Comparison BNP plasma level in left ventricular dysfunction 
 
Left Ventricular Function Left Ventricular Function P 
(95% confidence interval) 
Systolic dysfunction Normal 0.003 
Diastolic dysfunction Normal 0.006 
Systolic dysfunction Diastolic dysfunction 0.691 
 
  
According to comparison of BNP plasma level to the 
left ventricular function of patients suffering from acute 
coronary syndromes, there was a significant difference 
both between patients with systolic dysfunction and 
patients with normal ventricular function and between 
patients with diastolic dysfunction and patients with 
normal ventricular function (p < 0.05). On the other 
hand, according to comparison of BNP plasma level to 
the left ventricular function of patients suffering from 
acute coronary syndromes, there was no significant 
difference between patients with systolic dysfunction 
and patients with diastolic dysfunction (p = 0.691) 
(Table 3). 
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Table 4. Ejection fraction to left ventricular function 
 
Left 
ventricular 
function 
Number 
 
n 
Mean EF 
% 
Standard 
deviation 
Minimum 
% 
Maximum 
% 
ANOVA 
test 
P 
Systolic 
dysfunction 
9 44.1 5.2 35 49.1  
 
Diastolic 
dysfunction 
10 64.5 9.2 54.3 79.2 0.0001 
Normal 6 61.6 8.8 53.3 76.2  
 
 
The mean of ejection fraction of patients suffering from 
acute coronary syndromes with systolic dysfunction was 
44.1% and that of patients suffering from acute 
coronary syndromes with diastolic dysfunction was 
64.5%. Meanwhile, the mean of ejection fraction of 
patients with normal left ventricular function was 61.6% 
(Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Relationship of BNP plasma level, ejection fraction and ventricular function 
 
 
It was obtained that there was 1 patient (11.1%) 
suffering from left ventricular systolic dysfunction with 
a BNP plasma level less than 100 pg/ml. In the mean 
time, there was 1 patient (10.0%) suffering from left 
ventricular diastolic dysfunction with a BNP plasma 
level less than 100 pg/ml. All patients with normal 
ventricular function had BNP plasma level less than 100 
pg/ml as well (Table 5). 
 
Ejection 
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Table 5. Left ventricular dysfunction with cut of point 100 pg/ml 
 
BNP Level Left ventricular 
function ≤ 100 pg/ml > 100 pg/ml 
Total 
Systolic 
dysfunction 
1 
11.1% 
8 
88.9% 
9 
100.0% 
Diastolic 
dysfunction 
1 
10.0% 
9 
90.0% 
10 
100.0% 
Normal 6 
100.0% 
0 
0% 
6 
100.0% 
Total 8 
32.0% 
17 
68.0% 
25 
100.0% 
 
The number of patients suffering from acute coronary 
syndromes who experienced cardiovascular events 
within 30 days was 10 patients (40%), 3 of them were 
deceased and the remaining 7 patients suffered from 
heart failure. Among the 10 patients who experienced 
cardiovascular events, 3 persons were diagnosed acute 
large anterior wall myocardial infarction, 2 persons 
were diagnosed acute anteroseptal myocardial 
infarction, 1 person was diagnosed acute anterior wall 
myocardial infarction, 2 persons were diagnosed acute 
inferior wall myocardial infarction, and the last 2 
persons were diagnosed acute inferior and right 
ventricular myocardial infarction.  
The mean of BNP plasma level of patients suffering 
from acute anterior wall and acute large anterior 
myocardial infarction is 403 pg/ml, and the mean of 
BNP plasma level of other types of infarction is 177.4 
pg/ml. Among 3 patients who were deceased, 2 patients 
were due to cardiogenic shock and the remaining 1 
experienced ventricular fibrillation. The 3 cases of 
mortality occurred to patients suffering from acute large 
anterior wall and acute anterior wall myocardial 
infarction. The mean of BNP plasma level of the 
deceased patients was 582.33 pg/ml.  
 
Table 6. BNP Plasma Level In Cardiovascular Events 
 
Cardiovascular 
events 
Number 
n 
Mean 
pg/ml 
Standard 
deviation 
Minimum 
pg/ml 
Maximum 
pg/ml 
t test 
P 
Yes 10 392.30 157.14 248.00 713.00 
No 15 118.67 78.53 14.00 234.00 
0.0001 
 
The mean of BNP plasma level of patients who 
experienced cardiovascular events was 392.30 pg/ml, 
and that of patients who did not experience 
cardiovascular events was 118.67 pg/ml. The minimum 
limit of BNP plasma level of patients who experienced 
cardiovascular events was 248 pg/ml, and the maximum 
limit of BNP plasma level of patients who did not 
experience cardiovascular events was 234 pg/ml. The 
difference of BNP plasma level between patients who 
experienced cardiovascular events and patients who did 
not experience cardiovascular events was fairly 
significant (p = 0.0001) (Table 6). 
 
 
Table 7.Left Ventricular Dysfunction To Cardiovascular Events 
 
Cardiovascular Events Total Left Ventricular function 
Yes No  
Systolic dysfunction 6 
66.7% 
3 
33.3% 
9 
100% 
Diastolic dysfunction 4 
40% 
6 
60.0% 
10 
100% 
Normal 0 
0% 
6 
100% 
6 
100% 
Total 10 
40.0% 
15 
60% 
25 
100% 
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The cardiovascular events within 30 days were occurred 
in 10 patients (40%) suffering from acute coronary 
syndromes, 6 of them (66.7%) happened to patients with 
systolic dysfunction and the remaining 4 (40.0%) 
happened to patients with diastolic dysfunction. And 
there were no cardiovascular events among patients 
with normal left ventricular function (Table 7). 
 
 
DISCUSSIONS 
 
This study was carried on patients suffering from acute 
coronary syndromes in all clinical spectrum including 
acute ST elevation myocardial infarction, acute non ST 
elevation myocardial infarction and unstable angina, 
and there was no history of heart failure. Clinical 
evaluation on patients suffering from acute coronary 
syndromes is extremely important to determine 
complication and prognosis. Early finding of left 
ventricular dysfunction due to acute coronary 
syndromes is useful to give the optimum therapy and to 
prevent heart failure that ultimately worsens the 
coronary perfusion. 
 
In the current study, it was obtained that 76% of patients 
suffering from acute coronary syndromes experienced 
left ventricular dysfunction. The systolic dysfunction 
happened in 40% of them, and the diastolic dysfunction 
happened to the remaining 36%. The mean of BNP 
plasma level of patients with either systolic or diastolic 
dysfunction was significantly higher than in patients 
with normal left ventricular function. The mean of BNP 
plasma level of patients with systolic dysfunction was 
301.11 pg/ml and that of patients with diastolic 
dysfunction was 273.70 pg/ml, which was not 
significantly difference (p = 0.691). In contrast, it was 
obtained a significant difference of the increase of BNP 
plasma level that happened to patients with systolic 
dysfunction (p = 0.003), and the increase of BNP 
plasma level of patients with diastolic dysfunction 
differed significantly in comparison with that of patients 
suffering from acute coronary syndromes with normal 
left ventricular function (p = 0.006). 
  
On a guinea pig suffering from transmural myocardial 
infarction, the gene expression level of BNP on left 
ventricle increased within 4 hours after ligating 
coronary vessels and the level of BNP on non-infarcted 
tissue equals to that on infarcted tissue. Being gained 
from the evaluation of BNP plasma level of the guinea 
pigs, the increase of BNP plasma level was 5 times on 
the first day and 7 times on the third day. On the other 
studies, it was proved that BNP plasma level of patients 
suffering from unstable angina was higher than patients 
suffering from stable angina or normal people (Maisel 
A, 2001). Myocardial ischemia results in down 
regulation contraction as a conservative adapting 
response of the myocyte and consequently it will reduce 
the energy necessity in order to maintain viability. 
Myocardial infarction can result in either ventricular 
systolic dysfunction or ventricular diastolic dysfunction 
(Nobuyoshi M et al, 1991).  
 
The mean of BNP plasma level of patients suffering 
from acute myocardial infarction (419.1 pg/ml) in this 
study was significantly higher than that of patients 
suffering from unstable angina (124.5 pg/ml). The 
increase of BNP level was in line with regional 
disturbances of the ventricle. The experimental study 
proved that there was an immediate increase to the 
expression of BNP mRNA on myocyte located at the 
border of infarcted area (it was likely influenced by the 
change of growth factor and the expression of basic 
fibroblast growth factor). The stimulation of BNP 
increase was also affected by the increase of wall stress 
that directly influenced by the process of infarction. On 
a further process, as a result of the existence of 
ventricular load, it would enhance the stimulation of 
BNP increase. The increase of BNP produced systemic 
effect, natriuresis and vasodilatation that formed 
protection mechanism to the expansion of infarction. 
 
The mean of BNP level of the deceased patients was 
1582.33 pg/ml and all were with acute anterior wall and 
acute large anterior wall myocardial infarction. The 
causes of the mortality were cardiogenic shock and 
ventricular fibrillation in this study. At least there was 
40% of myocardial damage of the left ventricular 
muscle mass from the autopsy conducted on patients 
with cardiogenic shock (Daly-Nee C et al, 1999) The 
increase of BNP plasma level during the period of post 
myocardial infarction had a relationship with the 
infarction area, the decrease of ejection fraction, and the 
increase of heart failure risk and death (Nobuyoshi M al, 
1991).  Ventricular dilatation that occurred after acute 
myocardial infarction was repetitively related to 
ventricular remodeling. On the basis of Laplace law, the 
thinning and dilatation of infarction area can increase 
ventricular wall tension during the systolic period and 
diastolic period (Daly-Nee C et al, 1999). 
 
In the study on 72 patients suffering from symptomatic 
ventricular dysfunction with ejection fraction less than 
50%, BNP can be used to predict the increase of left 
ventricular diastolic end pressure. The other study has 
proved the increase of left ventricular diastolic end 
pressure 18 mmHg higher with sensitivity 81% and 
specificity 85% (Braunwald E, 2001). 
 
The stimulation of BNP release is influenced by left 
ventricular wall stretch and overload volume. BNP is a 
distress hormone that is specific to ventricular 
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disturbance in comparison with other groups of 
natriuretic peptide. BNP in blood circulation regulates 
blood pressure and fluid balance. BNP acts 
physiologically through the receptor that makes a bond 
with guanylate cyclase on natriuretic peptide receptor A 
(NPR-A). NPR-A is found in various tissues that 
catalyze the conversion of guanosine triphosphate to 
cyclic guanosine monophosphate (cGMP). cGMP 
produces a potent vasodilator effect and acts as a second 
messenger BNP. BNP possesses natriuresis and diuresis 
effects. BNP excretes sodium and water by increasing 
glomerulal filtration rate and by inhibiting sodium 
reabsorption in kidneys. BNP prevents the effect of 
renin angiotensin system by reducing secretion of 
aldosteron and renin that causes the decrease of blood 
pressure and extracellular fluid volume. BNP is retaken 
from plasma by means of 2 different mechanisms, that 
is to say endocytosis and enzyme degradation by 
endopeptidase (Hama N, 1995: Levin ER et al, 1998: 
Lainchbury JG  et al, 2002) 
 
In this study, 24% of patients suffering from acute 
coronary syndromes have normal left ventricular 
function. All patients suffering from acute myocardial 
infarction that possessed normal left ventricular function 
were treated with thrombolytic agent in order to gain a 
reperfusion. If ischemia occurred short lasting by 
reperfusion, the major molecule is not damage and 
myocard disturbances can be reversible (Nobuyoshi M 
et al, 1991).          
 
The diastolic dysfunction would be found in patients 
suffering from acute coronary syndromes whose BNP 
plasma level more than 97 pg/ml and echocardiography 
result without systolic dysfunction. On the other hand, 
the normal diastolic function would be found in patients 
suffering from acute coronary syndromes without 
systolic dysfunction and BNP plasma level less than 64 
pg/ml. 
 
Approximately 40%-50% of patients that were 
diagnosed heart failure had normal systolic function that 
implied the existence of diastolic dysfunction. Diastolic 
heart failure could not be differentiated by anamnesis, 
physical diagnostic, chest x-ray and electrocardiogram. 
It required the measurement of ventricular pressure and 
ventricular volume to optimize the evaluation of 
diastolic dysfunction measurement. This approach 
needed an invasive technique or echocardiography 
evaluation that needed time and measurement technique 
to be used to value diastolic property characteristic 
(Crilley JG & Farrer M, 1999) 
 
Appleton et al measured diastolic function by using the 
transmitral doppler velocity. The assessment using 
doppler on diastolic dysfunction and transmitral velocity 
pattern would be inconsistent due to the influence of 
heart rate, preload, afterload, contractility, valvular 
regurgitation, and the position of sample volume. On 
normal systolic condition, the simple blood examination 
in clinic to evaluate diastolic dysfunction will be very 
useful ((Crilley JG & Farrer M, 1999: Lubien E et al, 
2002). 
 
In this study, it was proven that the increase of BNP 
plasma of patients with normal systolic function had 
diastolic dysfunction. However, BNP plasma level 
cannot be used to differentiate between systolic 
dysfunction and diastolic dysfunction. In the mean time, 
by using echocardiography the existence of systolic 
dysfunction can be established. The low BNP plasma 
level of patients that previously checked with 
echocardiography without systolic dysfunction can be 
used to exclude diastolic dysfunction. 
 
The mean of BNP plasma level of patients suffering 
from acute coronary syndromes with cardiovascular 
events was significantly higher than that of patients 
without cardiovascular events within 30 days. Patients 
suffering from acute coronary syndromes with the 
increase of BNP plasma level more than 248 pg/ml 
would have a risk to experience heart failure or death 
within 30 days. In contrast, patients suffering from acute 
coronary syndromes with left ventricular dysfunction 
whose BNP plasma level less than 234 pg/ml would not 
have a risk to experience cardiovascular events. 
 
BNP that is used to predict the risk of patients suffering 
from acute coronary syndromes is not like traditional 
biomarker, that is to say BNP plasma has a role as 
contraregulator response against ischemia. The increase 
of BNP plasma level will have a relationship with the 
severity of ischemia and the degree of ventricular 
dysfunction (McClure S et al, 1998: Peacock WF, 
2002). 
 
The activation of neurohormonal system is a death risk 
after acute coronary syndromes. The relationship 
between BNP plasma level and long-term risk of death 
is an independent factor. The increase of BNP plasma 
level more than 80 pg/ml is indicating the activation of 
neurohormonal system on patients with heart failure. 
This limit is no different in acute coronary syndromes 
(Braunwald E, 2001).  On this study the use of the limit 
as of BNP 80 pg/ml or higher indicated the presence of 
left ventricular dysfunction and it was considered as 
normal ventricular function if BNP level was less than  
80 pg/ml. 
 
The measurement of BNP of patients with heart failure 
that was conducted on one study showed the increase of 
BNP plasma level resulted in 52% of patients would die 
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or need to be rehospitalized within 30 days. On the 
other hand, the decrease of BNP level of 84% of 
patients showed a favorable result. 290 patients 
suffering from NYHA I and II heart failure with the 
mean of ejection fraction of 37% showed the increase of 
BNP level more than 56 pg/ml can be used 
independently to predict the progress of heart failure 
and death. On other study, the increase of BNP level to 
predict the death was much better than that of age, ANP, 
ejection fraction of pulmonal artery pressure, sex, 
etiology of heart failure or NYHA class on 12-month 
evaluation (Braunwald E, 2001: Poulsen SH et al, 2001: 
Peacock WF, 2002) 
 
The study that compared normal people, patients 
suffering from coronary heart disease, and patients with 
heart failure showed that there was no increase of BNP 
level of patients suffering from coronary heart disease 
without ventricular dysfunction. On Veteran 
Administration Study, BNP level could be used to 
predict criticalness level of the patients, with the 
purpose of deciding whether the patients were supposed 
to be hospitalized or not. Patients that were hospitalized 
possessed the mean of BNP level 700 pg/ml, and 
patients that were not hospitalized had the mean of BNP 
level 254 pg/ml (Braunwald E, 2001: Peacock WF, 
2002) 
 
In other study on patients suffering from acute 
myocardial infarction, it was obtained that BNP can be 
used to predict left ventricular function, heart failure 
and long term survival rate. Patients suffering from 
myocardial infarction with the increase of BNP level 
were predicted having unfavorable prognosis that 
possibly reflected ventricular function disturbance. The 
study on 30 patients suffering from myocardial 
infarction showed BNP level 1 week post myocardial 
infarction had a relationship with heart remodeling. The 
BNP level had a relationship with the increase of left 
ventricular volume and the decrease of ejection fraction 
(Peacock WF, 2002: Struthers A, 2002) 
 
CONCLUSIONS 
 
Plasma BNP level can be used to detect the presence of 
diastolic as well as systolic LV dysfunction on 
echocardiography in early events of acute coronary 
syndromes. Moreover, plasma BNP level can also 
predict patients with cardiovascular events in 30-days 
after acute coronary syndromes.  
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